Index  by unknown
INDEX
A
Absolute claudication distance, initial claudication distance v,
s132
Acetylsalicylic acid, s248
Activated partial thromboplastin time, s65
Activated protein C, resistance to, assay for, s65
Acute limb ischemia
anatomic improvement in, s147
anticoagulant therapy in, s150
catheter-directed thrombolysis v surgical revascularization in,
s155
classification system for, s144
clinical categories of, s143
clinical classification of, s142
clinical outcomes in, s146
clinical presentation of, s135-136
clinical trial issues in, s164
combining treatments within trial groups in, s166
conditions mimicking, s138
definition of, s135
diagnosis of, urgency of, s144
differential diagnosis of, s137, 138
economic aspects of, s163-164
effectiveness assessment in, s147
endovascular procedures tor, s151-152
etiology of, s135
factors for intervention selection in, s151
follow-up care in, s160-161
functional status in, sl48
health-related quality of life in, s148
hemodynamic improvement in, s147
imaging in, s141
immediate management of, s150
management algorithm for, s161-163
motor function loss in, s137
outcome assessment methodology in, s145-146
patient history in, s136
perioperativc angiography in, sl55
physical examination in, s136-137
predicting outcome in, s143-144
procedural morbidity in, s147-148
procedural mortality in, s147-148
sensory function loss in, s137
severity levels in, s142-144
subcutaneous heparin in, s151
surgery in, s154-158
surgical technique in, s154-155
symptom recurrence in, s148
technical therapy success in, s146-147
therapeutic options in, s158
therapy of, s150
therapy success reportage in, s149
thrombolysis following arteriography in, s152
treating underlying lesion in, s159-160
treatment crossovers in, s166
trial cost-effectiveness analysis in, s167
trial end point selection in, s166-167
trial entry criteria in, s164
trial failures in, s165
trial intention-to-treat rule in, s164-165
trial standardizing reporting practices in, s165-166
trial stratification treatment groups in, s165
Age
critical limb ischemia and, s22
intermittent claudication and, s9, s10
Arnbulation, s264
Aminophylline, s93
Amputation
as clinical trial end point, s284
cost of, s278-279
incidence of, s21-22, s24-25
indications for, s267
level of, s26
numbers of, s26
primary, s267-268
risk factors for, s25-26
secondary, s268
selection of, s268-269
technical principles of, s270
Amputee, fate of, s26-27
Anesthesia, s237
Aneurysm, thrombosed popliteal, management of, s161
Angiogenesis, gene-induced therapeutic, in critical limb ischemia,
s200-201
Angiography, s256
alternatives to, s72
in intermittent claudication, s71
perioperative, s155
Ankle pressure, in critical limb ischemia, s178
Ankle pressure measurement, s66-67
Ankle pulse
detection of, s6
intermittent claudication and, and ankle-brachial pressure
index, s7
Ankle-Brachial Pressure Index, 567, s254-255
cardiovascular disease and, s15
claudication progression and, s17 -18
in critical limb ischemia, s189
intermittent claudication and, and pulse, s7
measurement of, s7-8
Antibiotics, s237
in ulcer therapy, s195
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Anticardiolipin antibody assay, s65
Anticoagulant, s249
in critical limb ischemia, sl99
Anticoagulation, long-term, following thromboembolectomy,
5161
Antiphospholipid antibodies, test for, s65
Antiphospholipid syndrome, s64
Autiplatelet therapy, s82, s92
in critical limb ischemia, s199
Antithrombin assay, s65
Antithrombin deficiency, s64
due to low-protein state, s64
Aortobifemoral bypass, s205
patency following, s114
Aortoiliac disease
endovascular treatment of, s214-215
preferred therapeutic options for, s215
surgical treatment of, s205
Aortoiliac endarterectomy, s205-207
Aortoiliac percutaneous translurninal balloon angioplasty, s98
Aortoiliac reconstruction, s239
Aortoiliac stent, sl 01
indications for, s102
Arterial dissection, s139
Arterial thrombosis, due to hypercoagulable state, s139
Arterial trauma, s139
Arteriovenous fistula, s221
Arteritis, s139
Arthritis, of hip, differential diagnosis of, s59
Atheroembolism, s138-139
Atherosclerosis
evaluation for, s65-66
systemic, progression and, s18
Axillobifernoral bypass, s115
Axillofemoral bypass, s207-208
Axillounifemoral bypass, s211
B
Bakers cyst, symptomatic, differential diagnosis of, s59
Basle study, s16
Beraprost, s90, 91
Biochemical study, in intermittent claudication, s62-63
Blood, ultraviolet irradiated autologous, s263
Blood lipid study, in intermittent claudication, s63
Buerger's disease, s58-59, s185, s187
claudication due to, s59
Buflomcdil, s90, s91
Buttock, differential diagnosis of, s59
C
Calf, intermittent claudication of differential diagnosis of, s59
Cancer-associated throrn bosis, s64
Capillary microscopy, in critical limb ischemia, s180
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Cardiovascular disease
ankle-brachial pressure index and, s15
peripheral arterial disease and, sl S
Cardiovascular morbidity prevention trial, in intermittent claudi-
cation, s133-134
Cardiuvascular mortality prevention trial, in intermittent claudi-
cation, s133
Carnitine, s93-94
Catheter-directed thrombolysis, surgical revascularization )', in
acute limb ischemia, s155
Causalgia, s184
Cerebrovascular disease, peripheral arterial disease and, s14-15
Chelation therapy, s265
Chronic compartment syndrome, s57-58
differential diagnosis of, s59
Chronic critical limb ischemia
definition problems in, s169-171
historical background in, s168-169
nomenclature in, s168
proposed definition of, s170
Chronic subcritical ischemia, s170-171
Cigarette smoking, s80
Cilostazol, s90, s91, s92
Cinnarizine, s90
Claudicanr, s54
coronary artery disease in, s20
tate ot~ s20
five-year fate of, s21
Claudication, s54
Claudicator, s54
Clinical trial
additional variables in, s286
adjuvant pharmacotherapy in, s286-287
constant ]J graded treadmill exercise protocol in, s131-132
design of, in critical limb ischemia, s281-282
end point selection in, s166-167
end points fur, s131, s133
entry criteria in, s286
inc1usivity ]J exclusivity in, s129, s282-283
operator variability in, s286
outcome reporting timing in, s285
patient stratification in, s283-284
patients entered in, s287
possible primary end points in, of critical limb ischemia, s284-
285
quality of life measurements in, s133
secondary end points in, s132-133
secondary interventions in, s287
standardizing reporting practices in, 5165-166
statistical ]J clinical significance in, s132
stratification in, s130-131
stratification treatment groups in, s 165
treatment crosssovers in, s166
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Coarctation, claudication due to, s59
Color flow duplex scanning, s255-256
in intermittent claudication, s71-72
Conduit, choice of, s218-219
Consensus process
caveat for, s3-4
essential criteria for,s 1
history of, sl, s2
methodology of, sl , 54
objectives of,s 1
Coronary artery disease
in claudicants, s20
peripheral arterial disease and, s14-15
Coronary Artery Surgery Study, 519
Cost(s)
of critical limb ischemia therapy, s275, 5276, s277-280
of diagnostic procedures, s275
fixed, s48
health care , 546-47
intangible, s47-48
opportuniry. se?
semi-fixed, 548
tangible non-health care , 547
variable, s48
Cost data
collection of, 546
computation of, s46-47
Cost minimization analysis, s48
Cost-benefit analysis, 548-49
Cost-effectiveness, in intermittent claudication
of antiplatelet therapy, 5124-125
oflipid control, 5125-126
Cost-effectiveness analysis, 548
Cost-utility analysis, s48
Coumarin, 5249
ill acute limb ischemi a, s160
Cramps, night, 5185
Critical limb ischemia
age and, s22
ankle pressure in, s178
basic treatment of,s19 3-194
card iovascular events in, s287
changing outcome of.,523-24
clinical definition of, 5170
clinical trial issues in, 5281 -288
contralateral leg in , s287
current criteria for, high-risk patients not covered bY, s171
definition of, 521
diabetes and, 523
diagnostic evaluation in, objectives for, 5182
differential diagnosis of, 5184-185
economic aspects of, 5274
effectiveness measures in ,s190
Index 8291
foot care in, 5194
history of, 5176
imaging in, s180-181
incidence of, 521-22
inrerventio nal options in, risks of, 5181-182
interventio nal treatment of, 5204
investigations for, s178
life-threatening coexisting disease therapy in, 5194
management algorithm for, 5274
management plan in, 5173-175
microcirculatory investigations in, s179
microcirculatory pathophysiology in, 5171-173
rnultidisciplinary team approach in, s173-174
outcome assessment methodology in, 5188-190
patient audits in, 5175
patient fate in, s23, 524, s25
patient management costs ill, 5279-280
pharmacotherapy for, 5197-201
physical examination in, s176-177
prevalence of, 521-22
prognosis in,s171
progression of, s282
reporting standards definition of, s170
risk factor control in, 5195-196
risk factors for, 522-23
risks odds ratio in, for mortality, s22
secondary interventions in, s287
smoking and, s22
sympathectomy, s265
testing for, 5178, 5180, s182
toe pressure in, s178-179
treatment of, 5192-193
trial secondary end points in, s286
Crossover bypass graft, long-term results of, 5211
Cyclosporin, 5251
Cyst , popliteal, 5139
D
Decisio n modeling, in peripheral arterial disease therapy, s51-52
Defibrinogenating agent, ill critical limb ischemia, 5200
Defibroride, s93
Descriptive instru ment, 537
Dextran, s249, 590
Diabetes mellitus, 5237-238
claudication progression and ,s17
critical limb ischemia and, sl96, s23
foot in,s 173
in termittent claudicati on and, s56 -57
neuropathic ulcer of, s186
peripheral arterial disease and , s11, s80
Diabetic neuropathy, s184
Diabetic patient, evaluating, considerations in, 568
Diagnosis-Related Group, reimbursement schedule for, s48
8292 Index
Dilute Russell Viper Venom Test, s64, 65
Doppler arterial studies, s141
Doppler pressure measurement, s269
Doppler velocity wave form analysis, s68-69
Duplex scanning, s141
Dysfibrinogenernia, s64
E
Economic evaluation
limitations of, s49-51
of peripheral arterial disease therapy, s45-51
principles of, s45-46
Edinburgh questionnaire, diagnostic performance of, s5-6
Effectiveness, efficacyv, s49
Embolus(i)
in acute limb ischemia, s135-136
atherosclerotic plaque disruption cholesterol, s138-139
peripheral, claudication due to, s59-60
Endovascular procedure
in acute limb ischemia, s155-158
complications of, s109-111
Epidural spinal cord stimulation, s264
Ergotism, s139
Erythrocyte sedimentation rate, in intermittent claudication, s63
Euglobulin lysis time, s65
EuroQol, s42
Exercise
rehabilitation with, s83-85
unsupervised, sl18
External iliac dysplasia, claudication due to, s59-60
F
Factor V Leiden, assayfor, s65
Factor V Lciden mutation, s64
Factor XII deficiency, s64
Fasciotomy, in acute limb ischemia, s159
Fernorofemoral bypass, s210-211
Femoropopliteal angioplasty, s227-231
Fcrnoropopliteal bypass
above-knee, vein)' prosthetic grafts for, s116
conduit for, s116
Femoropopliteal bypass graft, s222-223
Pernoropopliteal lesion
interventional treatment of, s106
morphological stratification of, s104-105
Femoropopliteal percutaneous translurninal balloon angioplasty,
s103
Femoropopliteal stent, s106, s109
patency of, s107-108
Fibrinogen, peripheral arterial disease and, s12
Fixed cost, s48
Fonatine stage, of peripheral arterial disease, s39
Foot
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in diabetes, s173
intermittent claudication of, s59
ulcer of, sl85
Framingham study, s16
Functional status
in acute limb ischemia, s148
improvement in, s190
Functional status assessment, s39-40
in intermittent claudication, s69-70
G
Gamble, standard, s41-42
Graft
failed, s238
proximal, s275
Graft surveillance, appropriate use of, s256-258
H
Health Utility Index, s42
Hematologic study, in intermittent claudication, s62-63
Hemodilution, in critical limb ischemia, s200
Heparin, s249
subcutaneous, in acute limb ischemia, s151
Heparin-induced thrombocytopenia, s64
Herniated disc, differential diagnosis of, s59
Hcxopal, s90
Hip
arthritis of, s59
osteoarthritis of, s58
Homocysteine, in peripheral arterial disease, s82
Hormone replacement therapy, s82
Hyperbaric oxygen, s263-264
Hypercoaguability, peripheral arterial disease and, s12
Hypercoagulable state
intermittent claudication and, s56-57
in peripheral arterial disease, s82
types of, s64
Hyperhomocysteinernia, s64
peripheral arterial disease and, s12
Hyperlipidemia
in critical limb ischemia, s196
intermittent claudication and, s56-57
peripheral arterial disease and, s12, s81
Hypertension
claudication progression and, s18
in critical limb ischemia, s195
intermittent claudication and, s56-57
in peripheral arterial disease, s81
peripheral arterial disease and, s12
Hypoplastic aorta, s209
I
Iliac artery occlusion, s100
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Iliac artery stenosis, endovascular therapy of, patency rates for,
5100
Iliac lesion
interventional management of, 599
morphological stratification of, 598
Iliac to femoral bypass, 5210
Imaging, in intermittent claudication, s70-72
Impaired glucose tolerance, peripheral arterial disease and, s 1.1
Infrainguinal bypass graft, 5222-226
Infrainguinal disease, s233-236, 5209-210
surgical therapy of 5217
Infrainguinal vein bypass grafting, s241
Infrapopliteal percutaneous transluminal balloon nngioplasty,
5108-109
Initial claudication distance, absolute claudication distance 1',
5132
Insulin resistance, peripheral arterial disease and, s11
Intangible cost, 547-48
Intention-to-treat rule, s164-165
Intermittent claudicant, definition of, 5170
Intermittent claudication
absolute l' initial claudication distance in, s132
by age group, s9, 10
ankle-brachial pressure index and, 57
antiplatelet therapy in, cost-effectiveness ot~ 5124-125
asymptomatic, prevalence ot~ 510
background treatment of, 5129-130
cardiovascular morbidity prevention trials in,s 133-134
cardiovascular mortality prevention trials in, 5133
clinical assessment of, 56, 556-62
clinical measures in, s75
clinical trial guidelines for, s 127
clinical trial objectives in, 5127
clinical trial reporting standards for, s127
clinical l' quality-of-lite outcomes in, 574-75
constant l' graded treadmill exercise protocol in, 5131-132
death in, causes of, 519-20
defining, problem with, 55
definition of, 554
diagnostic strategies for, s122-123
differential diagnosis of, s57, 559
economic aspects of 5122
cndovascular procedures tor, s97-111
genetic risk fur, 513
grading pulses in, s61
hemodynamic abnormalities in, 554-55
history in, 556-57
imaging techniques in, 570-72
incidence of, s8
invasive therapy in, indications tor, s79
lipid control in, cost-effectiveness of, s125-126
management algorithm for, s86
medical treatment of, 5122
Index 8293
in men, 511
mortality of, 518-19
natural history of, s129
nomenclature for, 554
nonfatal cardiovascular events in, s18
overall strategy in, 577-78
patient characteristics in, 554
patient-based outcomes parameters in, 575-76
pharmacotherapy for, 589-95
physical examination for, s60-61
prevalence of, s8-1O
progression from, to peripheral arterial disease, s79
progression of, sIS, s17
protective factors lor, s13
quality of lite measurements in, 5133
risk factor odds ratios for, s14
risk factors for, slO, s13, 556-57
routine tests for, s62-67
smoking and, 513
statistical p clinical significance in, s132
surgery for,s 113-120
therapeutic options for,s 117-120
treatment algorithm for, 5121
treatment costs tor, 5123-124
trial end points in,s133
trial secondary end points in, 5132-133
walking test in, 5130
worsening of, 515-16
Intimal hyperplasia, agents to inhibit, s250-251
Intramuscular gene transfer, in critieallimb ischemia, 5201
Isovolemic hemodilution, s92-93
J
[uxtarenal aortic occlusion, s208
K
Keranserin, s251, 592
L
Largininc, s251, 595
Laser Doppler fluxmetry, in criticallimh ischemia, 5179
Leg, ulcer at; differential diagnosis of, s185
Limb salvage, following chronic critical limb ischemia therapy,
s189
Lipid study, blood, in intermittent claudication, 563
Lumbar spine, osteoarthritis of, s58
Lumbar sympathectomy, 5116
Lupus anticoagulant, s65
M
Magnetic resonance angiography. s141
in intermittent claudication, 572
Malnutrition, s64
8294 Index
McMaster Health Index Questionnaire, 5118
Medical Outcome Study Short-Form 36, 540
Meta-analysis, in peripheral arterial disease therapy, 551-52
Metabolic syndrome, peripheral arterial disease and, 511
N
Naftidrofuryl, 590, 91
Naroparcil, 5251
Negative pressure application , 5264
Nephrotic syndrome, 564
Nerve root compression, 5184
differential diagnosis of, 559
Neuroischemic ulcer, 5186
Neuropathic ulcer, 5186
Neurospinal, 554
Night cramp, 5185
Nitric oxide, 5172, 5150
o
Obesity, 580
Occlusive arterial lesion, causes of, 559
Opportunity cost, 547
Osteoarthritis
of hip, 558
of lumbar spine, s58
Outcome measure(s)
objective, 538
symptomatic, 538-39, 575-76
Outcomes, efficacy measures for, 535-36
Outcomes research, in peripheral arterial disease, 535-36
Oxygen, hyperbaric, 5263-264
p
Pain, control of, in critical limb ischemia,s193-194
Patency
assisted primary, 537
definition of, 543
determination of, 542-43
primary, s37
PentoxifylJine, 589-91
Perceived health, 540
Percutaneous aspiration thrombectomy,s153
Percutaneous mechanical thrombectomy, 5153
Percutaneous transluminal balloon angioplas ty, 597
aortoiliac, 598
surgery I', 5119
Peripheral arterial claudication , coexisting risk factors for, 513
Peripheral arterial disease
catheter intervention in, 597
classification of, 539
claudication due to, 559
coexistin g vascular diseases and, 513-15
diabetes and,s11
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efficacy measures in, 535
epidemiology of, 55
fibrinogen and, 512
hemodynamic abnormalities in, 554-55
hypercoaguability and, s12
hyperhomocysteinemia and, 512
hyperlipidemia and, 512
hypertension and, 512
metabolic abnormalities of, s55
neurological abnormalities of, 555
outcomes research in, 535
risk factors for, 513, 514
smoking and, 511-12
Peripheral arterial disease therapy
decision modeling in, 551-52
economic aspects of, 545-51
economic evaluation limitations in, 549-51
meta-analysis in, 551-52
procedural complications of, 536
success criteria for, 536-38
technical success of, 536
Peripheral nerve pain, 558
Peripheral sensory neuropathy, 5184
Persistent sciatic arteries, claudication due to, 559-60
Plasma fibrinogen level, 565
Plasminogen
abnormal, 564
deficiency of, 564
level of, 565
Plasminogen activator deficiency, 564
Platelet aggregation test, 565
Platelet count, 565
Platelet reactivity, abnormal, 564
Popliteal aneurysm, thrombosed, management of, 5161
Popliteal artery aneurysm, thrombosed, 5139
Popliteal artery segment, isolated, 5218
Popliteal cyst, s139
claudication due to, 559-60
Popliteal entrapment, s139
claudication due to , 559-60
Procedural mortality, definition of, 5190
Propionyl-L-carnitine, 590, 591
Prostacyclin, s172
Prostaglandin, 594
Prosranoid, 594, s250
clinical trial of, 5198
in critical limb ischemia, s197, 5199
Prosthetic graft, surveillance of, 5256-258
Protein C assay, 565
Protein C deficiency, s64
Protein S assay, 565
Protein S deficiency, s64
Protein-losing enteropathy, s64
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Prothrombin mu tation , s64
Prothrombi n time, s65
Proximal revascularization, s216-217
Pscudoxantoma clasticurn , claud icatio n due to , s59-60
Psychological well-being, s40
Pulses
absent, s6
in acute limb ischem ia, sl 37
grading, for intermittent clnudicorion , s61
intermittent claudication and, s7
peripheral, detection of, s6
Pulse volume recording, s68
Q
Q uality-ad justed lite year, s4 1
Qu ality of life
assessment of, s40-4 1
in critica l limb ischemia, s28 5
impro vement in, s190
in interm ittent claud ication, s76
valu ing health-related, s41-42
Quality of Well-Being Scale, s42
Quest ionnaire
disease-specific health status, s30
Edinburgh, s5-6
generic health status, s39-40
for intermittent claudication detection, s5
WHO-Rose, s5
R
Radionuclide perfusion scan, in critical limb ischemia, sl79
RAND-36, s40-41
Reflex sympathetic dystrophy, s184
Reperfusion injury, s159
Revascula rization, surveillance fa llowing, s253 -258
Role function evaluat ion , s40
Rutherfo rd category, of peripheral ar terial d isease, s39
s
Segmental limb systo lic pressur e' measur ement, s67 -68
Segmental plethysmography, s68
Sem i-fixed cost , s48
Sensory neu ropathy, diabetic , s184
Short Form 36, s40 -41 , s76
Short-term morbidity, defin ition of, s190
Skin perfusion pressure management , s27 0
Smoking
cessation of, in critical limb ischemia, s195
claudication progression and , s17
critical limb ischemia and, s22
intermittent claudication and, s13
peripheral arterial disease and , sl1 -12
Spinal cord compression, s58
Index 5295
differential diagnosis of, s59
Spinal cord stimulation, epidural, s264
Spiral com pu ted tomography, in intermittent claudication, s72
Standard gam ble, s41-42
Srent, s245
multiple, cost- effectiveness of, s102
proximal, s275
STILE trial, s156
major findings of, s157
Stress test, alternative, s70
Summary receiver operating characteristic curve, s51
Surg ical revascularization, catheter-directed thrombolysis 1', in
acute limb ischemia, s155
Syrnpathcctorny
in acute limb ischemia, s151
in critical limb ischemia, 5265
lumbar, indications for, 5266
T
Thigh, differenti al diagnosis of, s59
Thoracofemoral bypass, s208
Thrombin time , s65
Thromboangitis obliterans , see Buerger's disease
Thr ombolysis
in acu te limb ischemia, 5151-152
contrai ndications to, s152-153
high-dose systemic, in arterial occlusion, s152
Thrombophilia, s63
Thrombosis
in acute limb ischemia, s135-136
arterial, due to hypercoaguJablc state, s139
associated with inflammatory bowel disease, s64
graft, s160
Ticlopidine, s90, 591, s248
Time trade-off, s41-42
Tobacco abuse, intermittent claudication and, s56-57
Toe pressure, in critical limb ischemia, s178-179
TOPAS trial, s156-157
Transcutaneous oxygen measurement, s269-27 0
in critical limb ischemia, s179
Trousseau's thrombosis, s64
u
Ulcer ts )
associated with hematologic disease, s187
diabetic neuropathi c, s186
etio logical classification of, s185
foo t, differential diagno sis of, s185
healing of, s284
leg , s185
systemic therapy of, s195
topical therapy of, s194
treatment of, s194-195
8296 Index
venous, s185-186
Ultraviolet irradiated autologous blood, s263
v
Valuational instrument, s37
Valuational measure, s37
Variable cost, s48
Vascular endothelial growth factor, s94
in critical limb ischemia, s201
Vascular registry
advantages of, s261-262
problems with, s261
Vasculitis, s186-187
Vasoactive drug( s)
in acute limb ischemia, s151
in critical limb ischemia, s200
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Vasodilator, s91
Vein bypass graft, surveillance of, 5256-258
Venous claudication, s57
differential diagnosis of, s59
Venous compression, intermittent, s264
Venous cuff, s221
Venous ulcer, s185-186
Veraparnil, s90, s92
Vitamin E, s93
w
Walking, s264
Walking distance, s75
Walking test, in intermittent claudication, s130
WHO-Rose questionnaire, diagnostic performance of, 55
